Treatment of lupus nephritis

Drugs

Volumn 63, Issue 3, 2003, Pages 257-274

  Hejaili, Fayez F ^a   Moist, Louise M ^a   Clark, William F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; ANCROD; ANTIMALARIAL AGENT; AZATHIOPRINE; BINDARIT; CLADRIBINE; CLARITHROMYCIN; COMPLEMENT COMPONENT C5B; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DORNASE ALFA; ERYTHROMYCIN; FISH OIL; FLUDARABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LINSEED OIL; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACNE; ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ANEMIA; ANGIONEUROTIC EDEMA; ANTICOAGULANT THERAPY; AVASCULAR NECROSIS; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CATARACT; CHILL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEMODIALYSIS; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPH NODE IRRADIATION; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PLASMAPHERESIS; PROTEINURIA; RASH; RETINOPATHY; REVIEW; RHABDOMYOLYSIS; SEIZURE; THROMBOCYTOPENIA; THROMBOSIS; TREMOR;

ADRENAL CORTEX HORMONES; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

EID: 0037275319     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363030-00002     Document Type: Review

References (144)

1. Leehey DJ, Katz AI, Azaran AH, et al. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1983: 2 (1 Suppl. 1): 188-96
2. Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. Medicine (Baltimore) 1999; 78: 148-66
3. Uramoto KM, Michet CJ. Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50
4. Urowitz MB, Gladman DD, Abu-Shakra M, et al. Evolving spectrum of mortality and morbidity in SLE. Lupus 1999; 8: 253-5
5. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167-75
6. Abu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in lupus erythematosus: results from a single center. J Rheumatol 1995; 22: 1265-70
7. Gourley MF, Austin III HA, Scott D, et al, Methylprednisolone and cyclophosphamide alone or in combination in patients with lupus nephritis: a randomized controlled trial, Ann Intern Med 1996; 125: 549-57
8. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57
9. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326: 1373-9
10. McLaughlin J, Gladman DD, Urowitz MB, et al. Kidney biopsy in systemic lupus erythematosus: survival analysis according to biopsy results. Arthritis Rheum 1991; 34: 1268-73
11. Schwartz MM, Lan SP, Bonsib SM, et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13: 273-83
12. Schwartz MM, Lan SP, Bernstein J, et al. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int 1992; 42: 743-8
13. Concato J, Shah N, Horwitz RI, et al, Randomized, controlled trials, observational studies, and the hierarchy of design of research designs. N Engl J Med 2000; 342: 1887-92
14. Felson DT, Anderson J. Evidence of superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of pooled analysis. N Engl J Med 1984; 311: 1528-33
15. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta analysis of clinical trials. Am J Kidney Dis 1997; 29: 193-9
16. Donadio JV, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993; 21: 239-50
17. Nossent HC, Koldingsnes W. Long term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-74
18. D'Cruz D, Cuadrado MJ, Mujic F, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheum 1997; 15: 275-82
19. Clark WF, Kortas C, Heidenheim AP, et al. Flaxseed in lupus nephritis: a two year non-placebo controlled crossover study. J Am Coll Nutr 2001; 20: 143-8
20. Chan TM, Li FK. Tang CS. et al. Efficacy of mycophenolate in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62
21. Boleis JN, Ioannidis JP, Boki KA. et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 569-70
22. Davis JC, Manzi S, Yarboro C, et al. Recombinant human DNase I (rhDNase) in patients with lupus nephritis. Lupus 1999; 8: 68-76
23. Wallace DJ, Goldfinger D, Pepkowitz SH, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 1998; 13: 163-6
24. Sesso R, Monteiro M, Sato E, et al. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994; 3: 107-12
25. Clark WF, Parbtani A, Naylor CD, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int 1993; 44: 75-86
26. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5
27. Steinberg AD, Muir J, Scott DE, et al. Approach to lupus nephritis based upon randomized trials. Contrib Nephrol 1992; 99: 46-54
28. Austin III HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
29. Clark WF, Balfe JW, Cattran DC, et al. Long term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis. Plasma Ther Transf Technol 1984; 5: 353-60
30. Liebling MR, McLaughlin K, Boonsue S, et al. Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 1982; 9: 543-8
31. Donadio Jr JV, Holley KE, Ferguson RH, et al. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971; 75: 165-71
32. Huskisson EC. Azathioprine. Clin Rheum Dis 1984; 10: 325-32
33. Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34: 2246-9
34. Boumpas DT, Austin III HA, Vaughan EM, et al. Risk for sustained ammenorrhea in patients with SLE receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 114: 366-9
35. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-51
36. Kahan BD. Drug therapy: cyclosporine. N Engl J Med 1989; 321: 1725-38
37. Favre H, Miescher PA, Huang YP. et al. Cyclosporine in the treatment of lupus nephritis. Am J Nephrol 1989; 9: 57-60
38. Tam LS, Li EK, Leung CB, et al. Long term treatment of lupus nephritis with cyclosporine A. QJM 1998; 91: 573-80
39. Fu LW, Yang LY, Chen WP, et al. Clinical efficacy of cyclosporine: a neural in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheum 1998; 37: 217-21
40. Austin III HA, Vaughan EM, Boumpas DT, et al. Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine [abstract]. J Am Soc Nephrol 2000; 11: A439
41. Yu Z, Lenon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune disease. N Engl J Med 1999; 340: 227-8
42. Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus associated thrombocytopenia. Arthritis Rheum 1990; 33: 1233-9
43. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-34
44. Cohen MG, Li EK. Limited effect of intravenous IgG in treating systemic lupus erythematosus associated thrombocytopenia. Arthritis Rheum 1991; 34: 787-8
45. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological changes in steroid resistant lupus nephritis by high dose intravenous gammaglobulin. Nephron 1989; 53: 303-10
46. Schifferli J, Leski M, Favre H, et al. High dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-8
47. Cayco AV, Perazella MA, Hayslett JP, et al. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8: 1788-94
48. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized double blind clinical studies in prevention of rejection. Transplantation 1997; 63: 39-47
49. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroid for prevention of acute rejection. Lancet 1995; 345: 1321-5
50. Corna D, Morigi M, Facchinetti D, et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-9
51. Glicklich D, Acharya A. Mycophenolate therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32: 318-22
52. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate therapy in lupus nephritis: clinical observation. J Am Soc Nephrol 1999; 10: 833-9
53. Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 10: 2103-8
54. Kingdon EJ, McLean AG. Psimenou E, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-11
55. Jones JV, Cumming RH, Bucknall RC, et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976; 1: 709-11
56. Wei N, Klippel JH, Huston DP, et al. Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1: 17-22
57. Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect survival of patients with SLE? Arthritis Rheum 1979; 22: 945-53
58. Dooley MAY, Falk RJ. Immunosuppressive therapy of lupus nephritis. Lupus 1998; 7: 630-4
59. Cathcart ES, Idelson BA, Scheinberg MAY, et al. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet 1976; 1: 163-6
60. Dosa S, Cairns SA, Lawler W, et al. The treatment of lupus nephritis by methylprednisolone pulse therapy. Postgrad Med J 1978; 54: 628-32
61. Kimberly RP. Pulse methylprednisolone in SLE. Clin Rheum Dis 1982; 8: 261-78
62. Ponticelli C, Zucchelli P, Banfi G, et al. Treatment of diffuse proliferative lupus nephritis by intravenous high close methylprednisolone. Q J Med 1982; 51: 16-24
63. Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992; 84: 681-9
64. Ginzler E, Diamond H, Kaplan D, et al. Computer analysis of factors influencing frequency of infection in SLE. Arthritis Rheum 1978; 21: 37-44
65. Staples PJ, Gerding DN, Decker JL, et al. Incidence of infection in systemic lupus. Arthritis Rheum 1974; 17: 1-20
66. Ettinger WH, Goldberg AP, Applebaum-Bowden D, et al. Dyslipoproteinemia in systemic lupus erythematosus: effects of corticosteroids. Am J Med 1987; 83: 503-8
67. Lukent BP, Raisz LG. Glucocorticoid induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-64
68. Klipper AR, Stevens MB, Zizic TM, et al. Ischemic necrosis of bone in SLE. Medicine (Baltimore) 1976; 55: 251-7
69. Zizic TM, Marcoux C, Hungerford DS, et al. Corticosteroid therapy associated with is chemic necrosis of bone in SLE. Am J Med 1985; 79: 596-604
70. Hochberg MC, Proshker MJ, Rogers EW, et al. Recommendation for the prevention and treatment of glucocorticoid induced osteoporosis: American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996; 39: 1791-801
71. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382-7
72. Saag KG, Emkey R, Scnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998; 339: 292-9
73. Cole EH, Glynn MF, Laskin CA, et al. Ancrod improves survival in murine systemic lupus erythematosus. Kidney Int 1990; 37: 29-35
74. Hariharan S, Pollak CE, Kant KS, et al. Diffuse proliferative lupus nephritis: long term observations in patients treated with ancrod. Clin Nephrol 1990; 34: 61-9
75. Wang Y, Hu Q, Madri JA, et al. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996; 93: 8563-8
76. Balow JE, Austin III HA. Progress in the treatment of proliferative lupus nephritis. Curr Opin Nephrol Hypertens 2000; 9: 107-15
77. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4
78. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-6
79. Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus. Int J Dermatol 1981; 20: 57-61
80. Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12: 692-4
81. Guglielmotti A, Colette I, Soldo L, et al. Bindarit effects on cellular mediators of kidney inflammation: role of the IL6 dependant pathway and modulation of MCP-1 production [abstract]. J Am Soc Nephrol 1997; 8: 473
82. Vigano G, Cotti E, Casiraghi F, et al. Bindarit reduces urinary albumin excretion (UAE) and urinary interleukin-6 (IL-6) in patients with proliferative lupus nephritis [abstract]. J Am Soc Nephrol 1995; 6 (3): 434
83. Nelson JL, Torez R, Louie FM, et al. Pre-existing autoimmune disease in patients with long term survival after allogenic bone marrow transplantation. J Rheumatol Suppl 1997; 48: 23-9
84. Burr RJ, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-14
85. David JC, Austin III H, Boumpas D, et al. A pilot study of 2-chloro-2-deoxyadenosine in the treatment of systemic lupus erythematosus associated glomerulonephritis. Arthritis Rheum 1998; 41: 335-54
86. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1: 55-60
87. Macanovic M, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 243-52
88. Illei GG, Klippel JH. Novel approaches in the treatment of lupus nephritis. Lupus 1998; 7: 644-8
89. Nestel PJ. Effects of N-3 fatty acids on lipid metabolism. Annu Rev Nutr 1990; 10: 149-67
90. Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentenoic acid prevents proteinuria and prolongs survival in NZB x NZW/F1 mice. J Clin Invest 1981; 68: 556-9
91. Robinson DR, Prickett JD, Makoul GT, et al. Dietary fish oil reduces progression of established renal disease in (NZB x NZW) F1 mice and delays renal disease in BXSB, and MRL/1 strains. Arthritis Rheum 1986; 29: 539-46
92. Kelley VW, Ferretti A, Izui S, et al. A fish oil diet rich in eicosapantaenoic acid reduces cyclooxygenase metabolites and suppresses lupus in MRL-1pr mice. J Immunol 1985; 134: 1914-9
93. Westberg G, Tarkowski A, Svalander C. Effect of eicosapentaenoic acid rich Menhaden oil and MaxEPA on the autoimmne disease of MRL/lpr mice. Int Arch Allergy Appl Immunol 1989; 88: 454-61
94. Von Shacky C. Prophylaxis of atherosclerosis with murine omega-3 fatty acids: a comprehensive strategy. Ann Intern Med 1987; 107: 890-9
95. Clark WF, Parbtani A. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis 1994; 23: 644-7
96. Hall AV, Parbtani A, Clark WF, et al. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. Am J Kidney Dis 1993; 22: 326-32
97. Clark WF, Parbtani A, Huff MW, et al. Flaxseed: a potential treatment for lupus nephritis. Kidney Int 1995; 48: 475-80
98. Clark WF, Muir AD, Westcott ND, et al. A novel treatment for lupus nephritis: lignan precursor derived from flax. Lupus 2000; 9: 429-36
99. Boumpas DT, Tassiulas IO, Fleisher TA, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 1999; 52: 67-75
100. Strober S, Field E, Hoppe RT, et al. Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med 1985; 102: 450-8
101. Chagnac A, Kiberd BA, Farinas MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84: 922-30
102. Buckheit JB, Olshen RA, Blouch K, et al. Modeling of progressive glomerular injury in humans with lupus nephritis. Am J Physiol 1997; 273 (1 Pt 2): F158-69
103. Clark WF. Treatment of lupus nephritis: immunosuppression, general therapy, dialysis and transplantation. Clin Invest Med 1994; 17: 588-601
104. Cheigh JS, Stenzel KH, et al. End stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993; 21: 2-8
105. Clark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: role of proteiniuria, hypertension and dyslipidemia in the progression of renal disease. Lupus 1998; 7: 649-53
106. Joven J, Villabona C, Vilella E, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323: 579-84
107. Love PE, Santoro SA. Antiphospholipid antibodies: anti-cardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98
108. Shin MD. Antiphospholipid antibody syndrome clinical conference. JAMA 1992; 268: 1451-3
109. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39: 1225-31
110. Bridoux F, Vrtovsnik F, Noël C, et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 1998; 13: 298-304
111. Espinoza LR. Antiphospholipid antibody syndrome: treatment. Lupus 1996; 5: 456-7
112. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-7
113. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8
114. Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910-20
115. Haider YS, Robert WC. Coronary arterial disease in systemic lupus erythematosus: quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16-37 years. Am J Med 1981; 70: 775-81
116. Massey ZA, Ma JZ, Louis TA, et al. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188-98
117. Massey ZA, Kasiske BL. Hyperlipidemia and its management in renal disease. Curr Opin Nephrol Hypertens 1996; 5: 141-6
118. Fried LF, Orchard TJ, Kasiske B for the Lipids and Renal Disease Progression Meta-Analysis Study Group. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9
119. Walker GW, Neaton JD, Cutler JA, et al. MrFit Research Group. Renal function change in hypertensive membranes of the multiple risk factor intervention trial: racial and treatment effects. JAMA 1992; 268: 3085-91
120. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8
121. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670-4
122. Buckheit JB, Olshen RA, Blouch K, et al. Modeling of progressive glomerular injury in humans with lupus nephritis. Am J Physiol 1997; 273: F158-69
123. Austin HA, Boumpas DT, Vaughan EM, et al. High risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Kidney Int 1997; 52: 538-58
124. Esdaile JM, Abrahamowicz M, MacKenzie T, et al. The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37: 359-68
125. UK Prospective Diabetes Study Group, Holman R, Turner R, Stratton I, et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: IKPDS 29. BMJ 1998; 317: 713-20
126. Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
127. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Anti-proteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74
128. Jermus G, Panagiotopoulos S, Tsalamandris C, et al. Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int 1997; 52: S87-92
129. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-94
130. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
131. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45
132. Petersen J, Alder S, Burkart J, et al. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 1995; 123: 754-62
133. The Gisen Group, Remuzzi G, Ruggenenti P. Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997; 349: 1857-63
134. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150: 1175-83
135. Vaughan Jr ED, Carey RM, Peach MJ, et al. The renin response to diuretic therapy: a limitation of antihypertensive potential. Circ Res 1978; 42: 376-81
136. MacGregor GA, Markandu ND, Singer DR, et al. Moderate sodium restriction with angiotensin converting enzyme inhibitors in essential hypertension: a double blind study. Br Med J (Clin Res Ed) 1987; 294: 531-4
137. Coplon NS, Diskin CJ, Petersen J, et al. The long term clinical course of systemic lupus erythematosus in end stage renal disease. N Engl J Med 1983; 308: 186-90
138. Kimberly RP, Lockshin MD, Sherman RL, et al. Reversible end stage lupus nephritis: analysis of patients able to discontinue dialysis. Am J Med 1983; 74: 361-8
139. Nossent HC, Swaak TJ, Berden JH, et al. Dutch working part on SLE: systemic lupus erythematosus: analysis of disease activity in 53 patients with end stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med 1990; 89: 169-74
140. Krishman G, Thacker L, Angstadt J, et al. Multicenter analysis of renal allograft survival in lupus patient. Transplant Proc 1991; 23: 1755-6
141. Ramos EL. Recurrent disease in renal allograft. J Am Soc Nephrol 1991; 2: 109-21
142. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9
143. Ishii Y, Nagasawa K, Mayumi T, et al. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 387-90
144. Clark WF, Jevnikar AM. Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Semin Nephrol 1999; 19: 77-85